741 related articles for article (PubMed ID: 30195192)
1. The changing landscape of naloxone availability in the United States, 2011 - 2017.
Freeman PR; Hankosky ER; Lofwall MR; Talbert JC
Drug Alcohol Depend; 2018 Oct; 191():361-364. PubMed ID: 30195192
[TBL] [Abstract][Full Text] [Related]
2. Association of Naloxone Coprescription Laws With Naloxone Prescription Dispensing in the United States.
Sohn M; Talbert JC; Huang Z; Lofwall MR; Freeman PR
JAMA Netw Open; 2019 Jun; 2(6):e196215. PubMed ID: 31225895
[TBL] [Abstract][Full Text] [Related]
3. Naloxone laws facilitate the establishment of overdose education and naloxone distribution programs in the United States.
Lambdin BH; Davis CS; Wheeler E; Tueller S; Kral AH
Drug Alcohol Depend; 2018 Jul; 188():370-376. PubMed ID: 29776688
[TBL] [Abstract][Full Text] [Related]
4. Legal changes to increase access to naloxone for opioid overdose reversal in the United States.
Davis CS; Carr D
Drug Alcohol Depend; 2015 Dec; 157():112-20. PubMed ID: 26507172
[TBL] [Abstract][Full Text] [Related]
5. Legal requirements and recommendations to prescribe naloxone.
Haffajee RL; Cherney S; Smart R
Drug Alcohol Depend; 2020 Apr; 209():107896. PubMed ID: 32058248
[TBL] [Abstract][Full Text] [Related]
6. Do naloxone access laws increase outpatient naloxone prescriptions? Evidence from Medicaid.
Gertner AK; Domino ME; Davis CS
Drug Alcohol Depend; 2018 Sep; 190():37-41. PubMed ID: 29966851
[TBL] [Abstract][Full Text] [Related]
7. Concurrent Naloxone Dispensing Among Individuals with High-Risk Opioid Prescriptions, USA, 2015-2019.
Guy GP; Strahan AE; Haegerich T; Losby JL; Ragan K; Evans ME; Jones CM
J Gen Intern Med; 2021 Oct; 36(10):3254-3256. PubMed ID: 33751410
[No Abstract] [Full Text] [Related]
8. Association between state Medicaid expansion status and naloxone prescription dispensing.
Sohn M; Talbert JC; Delcher C; Hankosky ER; Lofwall MR; Freeman PR
Health Serv Res; 2020 Apr; 55(2):239-248. PubMed ID: 32030751
[TBL] [Abstract][Full Text] [Related]
9. State laws that authorize pharmacists to prescribe naloxone are associated with increased naloxone dispensing in retail pharmacies.
Xu J; Mukherjee S
Drug Alcohol Depend; 2021 Oct; 227():109012. PubMed ID: 34482035
[TBL] [Abstract][Full Text] [Related]
10. Vital Signs: Pharmacy-Based Naloxone Dispensing - United States, 2012-2018.
Guy GP; Haegerich TM; Evans ME; Losby JL; Young R; Jones CM
MMWR Morb Mortal Wkly Rep; 2019 Aug; 68(31):679-686. PubMed ID: 31393863
[TBL] [Abstract][Full Text] [Related]
11. Orienting patients to greater opioid safety: models of community pharmacy-based naloxone.
Green TC; Dauria EF; Bratberg J; Davis CS; Walley AY
Harm Reduct J; 2015 Aug; 12():25. PubMed ID: 26245865
[TBL] [Abstract][Full Text] [Related]
12. Estimating naloxone need in the USA across fentanyl, heroin, and prescription opioid epidemics: a modelling study.
Irvine MA; Oller D; Boggis J; Bishop B; Coombs D; Wheeler E; Doe-Simkins M; Walley AY; Marshall BDL; Bratberg J; Green TC
Lancet Public Health; 2022 Mar; 7(3):e210-e218. PubMed ID: 35151372
[TBL] [Abstract][Full Text] [Related]
13. Increase in Naloxone Prescriptions Dispensed in US Retail Pharmacies Since 2013.
Jones CM; Lurie PG; Compton WM
Am J Public Health; 2016 Apr; 106(4):689-90. PubMed ID: 26890174
[TBL] [Abstract][Full Text] [Related]
14. State legal innovations to encourage naloxone dispensing.
Davis C; Carr D
J Am Pharm Assoc (2003); 2017; 57(2S):S180-S184. PubMed ID: 28073688
[TBL] [Abstract][Full Text] [Related]
15. The Opioid Crisis and the Physician's Role in Contributing to its Resolution: Step One--Prevention of Overdoses.
Wolfe S; Bouffard DL; Modesto-Lowe V
Conn Med; 2016; 80(6):325-34. PubMed ID: 27509638
[TBL] [Abstract][Full Text] [Related]
16. Opioid Overdose Prevention Programs Providing Naloxone to Laypersons - United States, 2014.
Wheeler E; Jones TS; Gilbert MK; Davidson PJ;
MMWR Morb Mortal Wkly Rep; 2015 Jun; 64(23):631-5. PubMed ID: 26086633
[TBL] [Abstract][Full Text] [Related]
17. Naloxone dispensing among the commercially insured population in the United States from 2015 to 2018.
Dunphy C; Zhang K; Guy GP; Jones CM
Prev Med; 2021 Dec; 153():106820. PubMed ID: 34599923
[TBL] [Abstract][Full Text] [Related]
18. Combative Treatment for Carfentanil Epidemic.
Konapur R; Searls N; Babcock CCK; Blough E; Patel I
J Addict Nurs; 2019; 30(1):2-3. PubMed ID: 30829994
[No Abstract] [Full Text] [Related]
19. Beliefs Associated with Pharmacy-Based Naloxone: a Qualitative Study of Pharmacy-Based Naloxone Purchasers and People at Risk for Opioid Overdose.
Donovan E; Case P; Bratberg JP; Baird J; Burstein D; Walley AY; Green TC
J Urban Health; 2019 Jun; 96(3):367-378. PubMed ID: 30747371
[TBL] [Abstract][Full Text] [Related]
20. Opioid overdose prevention through pharmacy-based naloxone prescription program: Innovations in health care delivery.
Bachyrycz A; Shrestha S; Bleske BE; Tinker D; Bakhireva LN
Subst Abus; 2017; 38(1):55-60. PubMed ID: 27164192
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
